Organoids have also been used in co-clinical trials to compare drug responses in organoids to clinical responses in the corresponding patients. Numerous studies have reported the successful use of organoids to predict therapy response in cancer patients. Recently, organoids have been adopted to ...
Patient-derived organoid (PDO) can recapitulate the biological features of the primary tumor it was derived from and has emerged as a promising drug-screening model for precision therapy. Here we show a proof-of-concept based on early clinical study entailing the organoids derived from the ...
organoid models may also be relevant for mimicking the genomic evolution of tumors, as was recently demonstrated by Lee et al., who studied genetic alterations occurring during bladder cancer tumor organoid culture compared with tumors developing in vivo20. The assessment of the mechanisms of resistan...
The article examines patient-derived non-small cells lung cancer (NSCLC) organoids (PDO) and their drug screening applications. Also cited are the possible use of PDOs in personalized cancer therapy, the creation of living NSCLC organoids biobank, and the anticancer a...
1d). Recently, glioblastoma (GBM) organoids were generated using this method, which maintained the histological and genetic characteristics, partial microvasculature and immune cells of the original tumour, providing a promising model for chimaeric antigen receptor T-cell (CAR-T) PDO biobanks Living...
Here we evaluate the capacity of patient-derived organoids (PDOs) to predict clinical drug response and functional consequences of tumor heterogeneity. We included 36 whole-genome-characterized PDOs from 23 OC patients with known clinical histories. OC PDOs maintain the genomic features of the ...
Among four patients who were platinum sensitive, resistant, or refractory, PDO drug responses correlated well with their clinical courses. Conclusion In vitro drug testing using ovarian cancer organoids is feasible and correlates well with patient clinical responses. These results may facilitate ...
In these cases, organoid models are used for validation, as opposed to screening, which could yield a broader pool of new combinations. A clinical study involving patients with early-stage CRC receiving neoadjuvant ICI have been used to evaluate the correlations between PDO-specific T cell ...
The paper explores PDO applications in screening and cancer treatment challenges. It discusses the future of PDOs in drug development and personalized treatment. 展开 关键词: cancer treatment clinical translation microfabrication technologies patient‐derived organoids therapeutic screening ...
Molecular profiling of tumor organoids was matched to drug-screening results, suggesting that PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses. We compared responses to anticancer agents ex vivo in organoids and PDO-based orthotopic mouse tumor...